The establishment of two paclitaxel‐resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines
- 17 April 2007
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 67 (9) , 955-967
Abstract
BACKGROUND: Although paclitaxel is used for hormone‐resistant prostate cancer, relapse definitely occurs later. Details of the molecular mechanism responsible for paclitaxel‐ resistance remain unclear.METHODS: We established paclitaxel‐resistant cells, DU145‐TxR and PC‐3‐TxR from parent DU145 and PC‐3. To characterize these cells, we examined cross‐resistance to other anticancer drugs. Expression of several potential genes that had been related to drug‐resistance was compared with parent cells by RT‐PCR and Western blotting. Methylation analysis of multiple drug resistance (MDR1) promoter was carried out using bisulfite‐modified DNA from cell lines. Knockdown experiments using small interfering RNA (siRNA) were also performed to confirm responsibility of drug‐resistance. Finally, cDNA microarray was performed to quantify gene expression in PC‐3 and PC‐3‐TxR cells.RESULTS: The IC50 for paclitaxel in DU145‐TxR and PC‐3‐TxR was 34.0‐ and 43.4‐fold higher than that in both parent cells, respectively. Both cells showed cross‐resistance to some drugs, but not to VP‐16 and cisplatin. Methylation analysis revealed that methylated CpG sites of MDR1 promoter in DU145 and PC‐3 cells were demethylated in DU145‐TxR cells, but not in PC‐3‐TxR cells. Knockdown of P‐glycoprotein (P‐gp), which was up‐regulated in resistant cells, by MDR‐1 siRNA restored paclitaxel sensitivity in DU145‐TxR but not in PC‐3‐TxR, indicating that up‐regulation of P‐gp was not always main cause of paclitaxel‐resistance. Microarray analysis identified 201 (1.34%) up‐regulated genes and 218 (1.45%) out of screened genes in PC‐3‐TxR.CONCLUSIONS: Our data will provide molecular mechanisms of paclitaxel‐resistance and be useful for screening target genes to diagnose paclitaxel sensitivity. Prostate 67: 955–967, 2007.Keywords
This publication has 33 references indexed in Scilit:
- Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysisLife Sciences, 2006
- Calcium-dependent Tetramer Formation of S100A8 and S100A9 is Essential for Biological ActivityJournal of Molecular Biology, 2006
- cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistanceBreast Cancer Research and Treatment, 2005
- P-Glycoprotein-Independent Apoptosis Induction by a Novel Synthetic Compound, MMPT [5-[(4-Methylphenyl)methylene]-2-(phenylamino)-4(5 H)-thiazolone]The Journal of Pharmacology and Experimental Therapeutics, 2005
- CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate CancerCancer Research, 2004
- Differential regulation of calcium homeostasis in adenocarcinoma cell line A549 and its Taxol‐resistant subcloneBritish Journal of Pharmacology, 2004
- Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cellsBiochemical and Biophysical Research Communications, 2004
- Bcl-2 Down-Regulation Is a Novel Mechanism of Paclitaxel ResistanceMolecular Pharmacology, 2003
- DocetaxelDrugs, 1996
- Taxol protects against calcium-mediated death of differentiated rat pheochromocytoma cellsLife Sciences, 1994